Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Blood. 2020 Aug 31:blood.2019004753. doi: 10.1182/blood.2019004753. Online ahead of print.
Blood. 2020.
PMID: 32870269